Here, we report antiviral activity of G418 against BVDV. Methods: Cell viability and virus yield reduction assays were used to investigate antiviral effects of G418 against BVDV. The expression of viral proteins and RNA were determined by western blot and real-time quantitive PCR, respectively. Results: We demonstrated that G418 (50% cytotoxicity concentration of 400 µg/ml) improved cell viability of Madin-Darby bovine kidney cells infected with a cytopathic strain of BVDV (NADL) in a dose-dependent manner with 50% effective concentration of 4 µg/ml.
Interestingly, close structural analogues with known properties as translation inhibitors similar to G418kanamycin and gentamicin -had no antiviral activity against BVDV. In addition, G418 inhibits virus yield of two different strains of BVDV (NADL and NY-1) without affecting viral RNA replication and translation or viral NS3 protein processing. Conclusion: Our data indicate that antiviral activity of G418 could result from interference with either the assembly or release of active virus, rather than the regulation of viral translation and replication. Thus, we propose the use of chemical analogues of G418 as antiviral therapeutics for treatment of viral diseases associated with the Flaviviridae family, such as hepatitis C virus, dengue virus, yellow fever virus, West Nile virus and others.
Hepatitis C virus (HCV) is a major cause of chronic liver disease, leading to liver cirrhosis and hepatocellular carcinoma [1] . It is a major pathogen infecting about 170 million individuals worldwide [1, 2] . The HCV RNA replicons, equipped with a neomycin resistance gene, allowed for the screening and identifications of new inhibitors of HCV intracellular replication. However, because replicons do not undergo a complete replication cycle, drug-screening programmes and mechanism of action studies based solely on these assays will not identify compounds targeting either early (virion attachment, entry and uncoating) or late (virion assembly and egress) stages of the viral replication cycle. In addition, it is possible that drugs that negatively affect neomycin resistance will also inhibit viral replication of HCV RNA replicons without affecting any of the viral mechanisms, creating a necessity to generate new screens to avoid this potential problem. Thus, aminoglycosides, such as neomycin analogues, which are potential antivirals, can never be used in an HCV replicon system to assess their antiviral potential.
Bovine viral diarrhoea virus (BVDV) is commonly used as a surrogate model for HCV infection. BVDV is a cytoplasmic positive sense RNA virus that belongs to the Flaviviridae family [3] . BVDV is known to cause severe lesions in the gastrointestinal tract and death in affected animals [4, 5] . Two biotypes, cytopathic (cpB-VDV) and non-cytopathic (ncpBVDV), can be isolated from infected animals [6] . However, only cpBVDV induces cytopathology in sensitive cell types, such as Madin-Darby bovine kidney (MDBK) cells.
BVDV shares a similar structural organization with HCV [7] . Like HCV, BVDV may use the low-density lipoprotein receptor to enter cells, uses a functionally similar internal ribosome entry site (IRES) for translation, uses an NS4A cofactor with its homologous NS3 protease, has a similar NS3 helicase/NTPase, has a Introduction mechanistically similar NS5B RNA-dependent RNA polymerase, and a seemingly equivalent mechanism of virion maturation, assembly and egress [7] .
In this study, we demonstrated that G418 (geneticin), a neomycin analogue widely used to select for transfected eukaryotic cells [8, 9] , inhibited cpBVDV (NADL)induced cytopathology and viral titres. G418 was also effective against ncpBVDV (NY-1). However, close structural analogues of G418 -gentamicin and kanamycinhad no affect on BVDV replication, suggesting structural specificity of G418 antiviral action.
Methods

Chemicals
All cell culture supplies were obtained from Invitrogen (Carlsbad, CA, USA). Unless specified, all other reagents were supplied by Sigma Aldrich (St. Louis, MO, USA).
Cells and viruses
MDBK cells (ATCC-CCL22) were grown in Dulbecco's modified Eagle's medium (DMEM) containing 4.5 g of glucose and 10% horse serum or in Minimum Essential Medium (MEM) with 10% irradiated fetal bovine serum free of antibodies to BVDV. Monolayers of 50-70% confluent cells were infected with plaquepurified cpBVDV strain NADL or ncpBVDV strain NY-1 in cell culture medium or mock infected with cell culture medium alone. The titre of cpBVDV used in our studies was sufficient to generate an input multiplicity of infection (MOI) of 0.1-0.5. After an initial incubation with virus for 1 h in a cell culture incubator (5% CO 2 , 37°C), the culture medium was changed to a fresh virus-free medium. For aminoglycosides or interferon experiments, drugs were added in required final concentrations to 50-70% confluent cell monolayers and then grown for the next 24-72 h.
Cell viability
MDBK cells were plated at a density 1-2×10 3 cells/ well in 96-well plates. On the following day after initial infection for 1 h, cells were washed and medium containing various concentrations of inhibitors were added to cells and incubated for the desired period of time. Cell viability was assessed using the resaruzin (almarBlue) indicator dye [10] . Quantitative analysis of dye conversion (AFU) was measured using a fluorescent plate reader with excitation/emission =550/580 nm. For toxicity studies, cell viability was expressed as a percent of control (AFU treated / AFU control ). The drugmediated protection of cell viability was expressed as percent survival as follows: % survival = [(AFU treated ) BVDV -(AFU control )BVDV] / [(AFU control )mock -(AFU control )BVDV], where (AFU treated )BVDV is the AFU of cells infected with BVDV and treated with a certain dilution of G418, (AFU control )BVDV is the AFU of cells infected with BVDV and left untreated, and (AFU control )mock is the AFU of cells mock infected and left untreated.
The 50% effective concentration (EC 50 ) was defined as the concentration of compound that offered 50% protection of the cells against virus-induced cytopathic effect and was calculated using logarithmic interpolation [11] .
Plate viability assay
MDBK cells were infected with NADL strain of BVDV at an MOI of 0.1 and distributed to a collagen-coated, 24-well plate. Cells were washed with phosphate-buffered saline (PBS) once after 6 h incubation at 37°C and 5% CO 2 , followed by addition of 2.5% methyl cellulose in the DMEM media containing 5% heat inactivated horse serum. Crystal violet staining was performed 5 days thereafter.
Determination of viral titres
Each well of a 12-well tissue culture plate was seeded with 1.5×10 5 MDBK cells and incubated at 37°C with 5% CO 2 for 24 h. Then, after removing the medium and rinsing the monolayer, cells were infected with BVDV at an MOI of about 1-2 to ensure efficiency of infection. Virus was then absorbed to cells at 4°C for 1 h and rinsed with cold PBS before the addition of required concentrations of G418 in growth medium. At 24 and 48 h post-infection, 0.25 ml aliquots of supernatant were harvested from each well and stored at -70°C before further analysis of viral titres. To determine viral titres, 10-fold dilutions (10 -1 -10 -8 ) of harvested supernatants were prepared and 50 µl of each dilution was plated into each of eight vertical wells per dilution of 96-well plate containing 50 µl of MDBK cells. Cells were then incubated at 37°C for 96-120 h and wells were scored for cytopathic effects (CPE) of the virus in order to determine viral titres according to Reed-Muench [12] . For ncpBVDV (NY-1), titre plates were fixed at 120 h with 20% acetone. Presence of virus was detected using BVDV MAb 20.10.6 with an immunoperoxidase test system.
Western blot analysis of viral NS3 protein
MDBK cells were infected with NADL strain of BVDV (MOI 10) in the presence or absence of 25 µg/ml of G418. Based on previous publications [13] , the 18-24 h post-infection time point was chosen to determine viral proteins in infected cells. In addition, we had previously demonstrated that in MDBK cells at 36 h with this high MOI, cell monolayers deteriorate very rapidly resulting in virus-induced cell death [14] . Thus, at 24 h post-infection, cell media was removed and cells were washed several times with PBS. Then, 2× concentrated electrophoresis sample buffer was added, cells were scraped from the dish and transferred to a microcentrifuge tube. To reduce viscosity, the samples were sonicated briefly or passed several times through a 26-gauge needle and boiled for 5 min. Fifteen micrograms of lysate sample were run on 10% SDS-PAGE and then transblotted. After blocking for 1 h in blocking buffer (5% dry milk in 0.05% Tween20 in PBS), membranes were incubated with primary antibody (MAb 20.10.6) [15] diluted 1:1,000 in blocking buffer for 60 min at room temperature and washed with 0.05% Tween 20 in PBS. After incubation with secondary antibody (anti-mouse IgG-HRP; Sigma) diluted 1:200 in blocking buffer for 60 min at room temperature, NS3 was detected with the Amersham ECL kit (Amersham Biosciences, Piscataway, NJ, USA) according to the manufacturer's instructions.
Detection of intracellular viral RNA by RT-quantitative PCR
A 24 h post-infection time point was used because overall viral RNA synthesis drops about two-to threefold in infected cells at 48 h post-infection (data not shown). This decrease in virus production in infected cell could be due to rapid cell death observed at this high MOI [14] . Thus, at 24 h post-infection with NADL strain of BVDV (MOI 10) in the presence or absence of 6 and 12 µg/ml of G418, medium was removed from the cell monolayers and washed with PBS three times. RNA was isolated using the RNAeasy kit (Qiagen, Valencia, CA, USA). A 50 µl RT-quantitative PCR (qPCR) was performed according to a previous publication [16] with forward primer corresponding to nucleotides 103-123 (5′-TAG CCA TGC CCT TAG TAG GAC-3′), reverse primer corresponding to nucleotides 176-196 (5′-GAC GAC TAC CCT GTA CTC AGG-3′) and TaqMan probe (6-carboxyfluorescein-AAC AGT GGT GAG TTC GTT GGA TGG CTT-6-carboxytetramethylrhodamine). PCR amplification consisted of 40 cycles of denaturation at 94°C for 20 s and annealing and extension at 62°C for 1 min in an ABI 7000 sequence detector. All samples were analysed in three replicate reactions.
Results
The morphology of cells infected with cpBVDV strain NADL (MOI 0.1-0.5) was practically indistinguishable from mock-infected control cells up to 6 h post-infection. However, by 16 and 24 h post-infection, a large number of infected cells were found to have extensive vacuolization of cytoplasm. By 36-48 h post-infection, about 50% of monolayers in all wells inspected for this study were partially destroyed. Further incubation of infected cells beyond 48 h post-infection resulted in a significant number of detached cells compared with control, resulting in significant reduction in crystal violet staining compared with control uninfected cells ( Figure 1A) .
Infection of MDBK cells with the ncpBVDV strain NY-1 did not result in cytoplasmic vacuolization or disruption of the cellular monolayer (data not shown).
Unexpectedly, G418 prevented the reduction in crystal violet staining in cells infected with NADL (Figure 1A ), suggesting inhibition of both viral spreading and cytopathology of NADL. To further investigate the potential antiviral and cytotoxic properties of G418, we used almarBlue (see Methods) to measure cell viability in control and infected cells treated with G418. We determined that G418 reduces viability in MDBK cells with a 50% cytotoxicity concentration of 400 µg/ml ( Figure 1B) . G418 prevented BVDV-induced CPE and increased cell viability of infected cells with an EC 50 of about 4 µg/ml ( Figure 1C ).
We also tested the antiviral activity of structurally similar G418 analogues (Figure 2A ), such as gentamicin and kanamycin A, and interferon, a common antiviral compound. Ring II is structurally identical in these three aminoglycosides. G418 and gentamicin also share structural identity of ring III. Neither of these drugs displayed any cellular toxicity at 12.5 µg/ml. However, among all tested aminoglycosides, only G418 significantly improved cell viability of infected cells to the levels comparable with the anti-BVDV activity of 100 IU/ml of interferon ( Figure 2B ). Furthermore, both gentamicin and kanamycin decreased the cell viability of infected cells at the tested concentration.
In spite of the literature that demonstrated aminoglycosides inhibited protein synthesis [17, 18] , the selective inhibition of viral cytopathology by only G418 suggested that the antiviral activity of this aminoglycoside is different from that commonly seen with inhibitors of viral translation and replication. To assess the effect of G418 on the translation of viral proteins, we used viral NS3 protein as a marker of BVDV translation at 24 h post-infection with an MOI of 10. A 24 h time point was used to demonstrate stable BVDV translation because at a high MOI (for example, 10) and later time points, viral cytopathology and cell death takes place, making analysis unreliable [14] . We demonstrated that although 25 µg/ml of G418 significantly inhibited virus-induced cytopathology, it had minimal effect on NS3 translation ( Figure 3A ). In addition, the 120 kDa band of NS2-NS3, commonly observed during the infection with ncpBVDV [19] , could not be detected in G418-treated or untreated cells infected with NADL ( Figure 3A ). This indicated that processing of NS2-NS3 was not modified by G418 treatment. The modest inhibition of NS3 expression by G418 at 24 h post-infection (11%) still can not explain the nearly 100-fold decrease in virus yield (Figure 4 ) from drug-treated, infected cells.
To determine if G418 regulates viral RNA replication, we measure intracellular accumulation of viral RNA using RT-qPCR. At 24 h post-infection with BVDV (MOI 5), there was no difference in the quantities of intracellular viral RNA in the absence or presence of different concentrations of G418 ( Figure 3B ). Furthermore, the inability of antiviral concentrations of G418 to inhibit intracellular accumulation of viral RNA at 24 h post-infection also suggests that viral NS5B, required for viral RNA synthesis, was successfully translated and processed.
To further characterize the antiviral action of G418, we determined the effect of G418 on virus yield from drug-treated, infected cells. We demonstrated that G418 at concentrations between 6 and 25 µg/ml inhibited viral titres of NADL by nearly 10-100-fold at 24 h post-infection ( Figure 4A ). This effect of G418 did not diminish after 48 h post-infection. We also tested G418 against ncpBVDV (NY-1). G418 clearly reduced viral production to levels below 10% of control during the first 48 h of infection ( Figure 4B ; 12 and 25 µg/ml of G418).
Discussion
Although the aminoglycoside G418 is widely used for the transfection of stable viral replicons of Flaviviridae viruses, there is no information regarding the effects of G418 on those RNA viruses directly. Herein, we now report that G418 protects MDBK cells against the cytopathic effects of the cpBVDV (NADL) and inhibits production of both cpBVDV (NADL) and ncpB-VDV (NY-1). 
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The G418-mediated prevention of BVBDV-induced cytopathology is concentration-dependent with an EC 50 of about 4 µg/ml. G418 was shown to have cell toxicity in sparse MDBK cell culture with CC 50 of about 400 µg/ml; thereby, the selectivity index of G418 in those cells is about 100. This antiviral and cytoprotective activity of G418 could be compared with those of interferon, which was shown to inhibit BVDV-induced CPE in our assays at 100 IU, which is an EC 90 of antiviral effects of interferon in BVDV system [20, 21] . G418mediated inhibition of virus-induced cytopathology can be observed up to 72-120 h post-infection, suggesting that G418 interferes with BVDV proliferation.
Structure-function analysis of G418, compared with its close structural analogues, kanamycin B and gentamicin, revealed that only G418 has an activity against cpBVDV. Other related aminoglycosides, such as tetracycline and fucidic acid, also had no antiviral activity against BVDV (data not shown). Structurally, ring II is common in all three compounds, suggesting that the specificity of G418 is not related to that ring. In addition, ring III in gentamicin and G418 are homologous, which suggests that ring I determines specificity of G418. This is somewhat different from the ability of those aminoglycosides that inhibit protein synthesis by binding to the A site of 30S ribosomes [22] , where the ability of G418 binding to RNA is assigned to its ring II [23] . Moreover, although it was recently demonstrated that G418, gentamicin and other related aminoglycosides could suppress stop codons and induce frame-shifting [24] [25] [26] [27] , only G418 was shown to inhibit virus-induced cytopathology, suggesting that the antiviral activity of G418 is different from inhibition or deregulation of translation.
We have chosen to investigate viral translation and replication at 24 h time point, which is when virusinduced CPE is not apparent and viral replication has achieved growth kinetics [13, 15] . We demonstrated that 25 µg/ml of G418 had no effect on the synthesis of the viral protein NS3 at 24 h post-infection. In addition, G418 did not block processing of NS2-NS3, a protein commonly observed in ncpBVDV, 
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suggesting that G418-mediated cytoprotection was not due to inhibition of processing of viral proteins. These data also suggest that G418 is unlikely to inhibit translation of host and viral proteases required for NS3 processing. Moreover, G418 did not inhibit viral RNA synthesis, suggesting that it did not affect viral polymerase (NS5B) formation and activity. These data suggest that G418, although being an inhibitor of protein synthesis [17, 18] , could possibly inhibit virus-induced cytopathology without blocking translation or replication. In addition, because virus entry precedes translation, it is highly unlikely that G418 blocks viral mechanisms before translation and replication. Moreover, gentamicin and kanamycin, both chemical and functional analogues of G418 and well-known inhibitors of translation, had no ability to block BVDV-induced CPE, suggesting that the antiviral action of G418 is likely to be different from inhibition of viral translation and replication. Although detailed investigation of the mechanism of antiviral activity of G418 is beyond the scope of this study, we speculate that G418 might inhibit assembly or release of active virus, or interfere with cellular factors responsible for the completion of the viral life cycle, which would be reflected in a reduction of viral yields. Further characterization of the release of active viral particles, by measuring infectious virus released into the cell medium, demonstrated that at 24 and 48 h post-infection G418 (6-25 µg/ml) inhibited virus yields of both NADL and NY-1 strains of BVDV. As 
the virus titre method used in our study measured only release of active infectious particles into the media, these data suggest that G418 might inhibit virus release. This hypothesis was also supported by the plate viability assays in which 3-25 µg/ml of G418 significantly reduced the spread of the virus in methycellulose-covered monolayers. Therefore, because aminoglycosides are thought to inhibit viral replication by interfering with virus entry and by inhibiting translation of viral RNAs [28] [29] [30] , the antiviral action of G418 against BVDV is uniquely different because its mechanism appears to be associated with events subsequent to viral translation, processing and replication.
G418 is proposed to be used in medicine as an antiparasitic agent [31] . In addition, administration of geneticin [32] or related gentamicin [33] is potentially helpful in the treatment of patients suffering from genetic disorders [34] . Therefore, it might be foreseeable to use G418 and its analogues against viral diseases associated with Flaviviridae, such as hepatitis C virus, yellow fever virus, dengue virus, West Nile virus and others.
